|
|
Vaccine Detail
|
PADRE-CMV Fusion Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PADRE-CMV Fusion Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007031
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: The peptide vaccine consists of the HLA A*0201–specific CTL epitope fused with PADRE, a non-CMV-specific TH cell epitope (La et al., 2012).
- Description: This is for Nonneoplastic Condition (NCT00722839).A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope (La et al., 2012; NCIT_C78820).
|
| Host Response |
|
|
| References |
La et al., 2012: La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. The Journal of infectious diseases. 2012; 205(8); 1294-1304. [PubMed: 22402037].
NCIT_C78820: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78820]
NCT00722839: [https://clinicaltrials.gov/show/NCT00722839/]
|
|
